NEURODEGENERATIVE DISEASE TREATMENT MARKET ANALYSIS
Global Neurodegenerative Disease Market: Key Developments
In June 2021, UniQure enrolled the first two patients in the higher-dose second cohort of a Phase I/II clinical trial in the United States for AMT-130, a micro ribonucleic acid (miRNA) gene therapy developed as a potential treatment for Huntington’s disease (HD).
In March 2021, Janssen Pharmaceutical received the United States Food and Drug Administration (FDA) approval for Ponvory (ponesimod) for the treatment of relapsing forms of multiple sclerosis (MS) in adults, including clinically isolated syndrome.
In October 2020, SK Chemical launched Ongentis, a Parkinson's disease treatment developed by the Portuguese pharmaceutical firm Bial. It was the first time a third- generation COMT (Catechol O-methyltransferase) inhibitor that contains Opicapone has been released in Korea.
In September 2020, Genentech announced the initiation of Phase III clinical trial program for its investigational medicine fenebrutinib in multiple sclerosis (MS), along with a higher-dose Phase III clinical trial program for Ocrevus (ocrelizumab) and a distinct Ocrevus trial to support African-American and Hispanic- and Latinx-American patients with MS.
Need a Custom Report?
We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports
Customize Now
Credibility and Certifications
9001:2015
27001:2022
Joining thousands of companies around the world committed to making the Excellent Business Solutions.
View All Our Clients
U.S.: 
U.K. : 
India : 
